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The current issue of CNS Neuroscience & Therapeutics contains
an interesting review by Kinecses and Vecsei [1] on the progress
in our knowledge related to the pathophysiological mechanisms
of Parkinson’s disease (PD) and on the development of putative
neuroprotective molecules. Since the seminal discovery by Oleh
Hornykiewicz that degeneration of DA neurons within the sub-
stantia nigra pars compacta (SNc) and the consequential dopamine
depletion in the striatum was the cause of neurological symptoms
in PD [2], thousands of reviews have been written on the subject,
some of them possibly superfluous. Nevertheless, we found this
last work enjoyable in terms of readability and in the way the au-
thors decided to tackle such a difficult enterprise. This brief litera-
ture review is obviously far from comprehensive or exhaustive, as
it would be impossible to summarize 50 years of fruitful research
in the PD field in a few pages. The main contribution of this re-
view is the general overview of the pathomechanism field and a
survey of the literature that it provides on the hot topic of neuro-
protection. Indeed, molecules able to slow and halt dopaminergic
neuronal loss represent the highest ambition of PD research, drug
companies and not least, patients. In recent years, research has
advanced to the point that halting the progression of PD, restoring
lost function, and even preventing the disease might be considered
realistic goals [3]. Nevertheless the ultimate goal of preventing PD
may take years to achieve, and no strong experimental confir-
mation hitherto is available for any of the compounds described
by Kinecses and Vecsei [1] and others that the authors have not
cited.
Essentially, this limit is likely to be due to the fact that we do
not extensively know the pathogenesis of the disease. Certainly,
the last two decades have seen a great progress in the knowl-
edge of the pathological mechanisms involved, generally in neu-
rodegeneration [4,5]. Mitochondrial dysfunction, excitotoxicity,
neuroinflammation, oxidative stress as well as protein aggregation
are considered to be the mean pathways leading to apoptosis [1,6].
The research aims to understand this intricate cascade of events as
of primary importance for the developing strategies to slow the
progression of PD.
Important clues concerning the pathogenesis of PD have been
achieved from epidemiological studies suggesting several envi-
ronmental factors linked to the disease. Pesticide or herbicide
exposure seem to cause an energy failure of dopaminergic neu-
rons subsequent to a mitochondrial dysfunction similar to that ob-
served in case of MPTP intoxication [7] and indeed, rural living
(where the use of pesticide is widespread) represents a risk factor
for sporadic PD [8]. On the other hand, genetic alterations leading
to abnormal protein aggregation, or excessive oxidative stress, or
alteration of apoptotic mechanisms account for the less common
familial cases [9–11].
In addition to the fact that we do not know what exactly causes

















molecules capable of modifying the disease course is that their
efficacy is regularly tested on animals rendered Parkinsonian by
dopaminergic toxins. Although these models are useful tools for
studying the physiopathology of PD, in the field of neuroprotec-
tion research, the obstacle is represented by the quite dissimilar
temporal course and anatomopathological features of these bench
models from the human disease. For instance, the MPTP, or the
6-OHDA intoxicated animal models (the most extensive used),
show a monophasic acute-subacute effect even when apply-
ing the intoxication protocol slowly, which does not replicate
the nigrostriatal neuodegeneration of idiopathic PD. Of interest,
post-mortem human studies have suggested that substantia nigra
dopaminergic neuron death begins at least 5–10 years before the
onset of motor symptoms [12–15] (Figure 1). Moreover, these an-
imal models are obtained by using specific dopaminergic neuron
toxin, whereas the human disease is characterized by the involve-
ment of an ample variety of neurotransmitters [16]. Although
PD is primarily clinically defined as an extrapyramidal disorder,
it is also characterized by wide range nervous system damage not
only motor, but even cognitive, behavioral, and autonomic. It is
enough to know that on the basis of a series of anatomic studies,
it was proposed that the PD pathology begins in the dorsal motor
nucleus of the vagus, in the medulla oblongata and that there is
also an early involvement of the olfactory bulb [17] (Figure 1).
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Figure 1 This ﬁgure shows how Parkinson’s disease progresses from the earliest symptoms (often nonmotor symptoms) to diagnosis and start of treatment
through to the early and advanced stages of the condition. Copyright c© 2010, Boehringer Ingelheim. All rights reserved.
If the current Parkinsonian animal models represent a poor tool
for predicting neuroprotective drugs, on the other hand, stud-
ies conducted on PD patients manifest other concerns. The pri-
mary pitfall is that many of the drugs proposed to interfere with
the disease course are clinically effective on the PD symptoms,
confounding the clinical assessments, that is, MAO-B inhibitors
or dopamine agonists. Moreover, nondopaminergic drugs such as
creatine might alter the measure outcome by giving a nonspe-
cific effect of a sense of well being. Thus, to overcome the prob-
lem of the symptomatic effects in PD progression of the suspected
neuroprotective molecules, the delayed-start clinical trial design,
also called the randomized-start design, has been performed [18].
This protocol is based on the assumption that if there is a disease-
modifying effect, the group treated with a placebo for the first half
of the study should be worse in comparison to the group treated
with the drug for the entire study. However, this kind of proto-
col has a fundamental drawback. For obvious medical/ethical rea-
son, the placebo-treated patients should not be composed of ad-
vanced PD patients requiring a considerable therapy, but by early
or mild PD subjects. However, these groups of patients, in com-
parison to advanced, manifest a slower progression rate of the dis-
ease and poor quantifiable changes in clinical scales. Even with a
long-lasting study, changes in clinical outcome could be difficult
to detect [19,20] and even if a neuroprotective effect is detected,
it could be linked to a preservation of compensatory mechanisms
rather than to a true neuroprotection.
Another way to measure the hypothetical neuroprotective ef-
fect is to quantify a specific biomarker of dopaminergic neuron
loss, to recognize the true effect on disease progression from the
symptomatic effects. Actually, brain radio assay imaging seems to
be appropriate for this goal: however, in two large clinical trials
[21,22], the dopamine agonists employed interfere with the radi-
oligand binding, hampering the results [23,24].
A point to be mentioned about the neuroprotection strategies
applied in human disease is the time lag between the clinical and
anatomopathological onset of the disease. However, dopaminer-
gic neuron loss precedes by years the clinical disease onset and
as soon as the first clinically clear motor symptom appears, the
ventrolateral area of the SNc is already severely destroyed (about
70% of neuron loss) [12,13]. In this context, it appears clear
that a hypothetical neuroprotection strategy in PD would start too
late to be significantly beneficial (Figure 1). How can we perform
neuroprotection before the clinical evidence of the disease? It is
clear that a key challenge would be to find an early marker of
the disease, which could identify individuals likely to develop the
disease [25].
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Recent research has thrown some light on this: numerous
potential biomarkers have now been identified, ranging from neu-
roimaging to wet biological markers such as blood and cere-
brospinal fluid (CSF) [26]. Compelling evidence has shown that
positron emission tomography (PET) or single photon emission
computed tomography (SPECT) imaging uses a radiolabelled com-
pound as a probe of dopamine transporters (DAT), sensitive
enough to detect a subclinical degeneration of the dopaminergic
system [27,28]. Hence, they can be very useful in studying the
progression of presynaptic dopaminergic degeneration, thus de-
tecting patients in the premotor phase of PD [29]. The American
Academy of Neurology (AAN) guidelines [30] also consider mag-
netic resonance imaging (MRI) as potentially useful for a differ-
ential diagnosis of PD from other forms of Parkinsonism. In addi-
tion, of potential interest for early diagnosis of PD is the evidence
that the sense of smell is affected in the initial stages of the neu-
rodegenerative process. Unfortunately, hyposmia has insufficient
specificity for smell testing to be used as a single screening test for
premotor PD. Recently, a two step approach of combining olfac-
tory testing and DAT SPECT imaging seems to be able to overcome
this drawback, having both high sensitivity and specificity in diag-
nosing premotor PD [31].
In conclusion, we would like to point out that the research
into neuroprotective molecules of proven efficacy still represents
a challenge for neuroscientists. The first difficulty is to prove the
real efficacy of the potential therapy, either in animal models or
in large cohorts of patients free from the pharmaceutical interests
of the big companies. Finally, although neuroprotective therapy
remains a higher priority in the field of PD, as well as of all neu-
rodegenerative diseases, at the same time, we believe that a neuro-
protective strategy is really successful when performed in the early
stages of the disease that unfortunately do not correspond to the
onset of motor deficits. Thus, parallel to exploration of molecules
modifying the disease course, we must improve our ability in pre-
motor diagnosis for an authentic advancement in the treatment of
PD. In reality, the promising results seem to please the researchers
and vested financial interests more than the patients. We do not
know if PD will be prevented, without doubt we can reduce the
risk so far known. Recently, a large body of experimental and epi-
demiological evidence has highlighted the paramount role of di-
etary factors in counteracting DA degeneration [32]. Therefore,
although rapidly advancing basic research is developing reliable
diagnostic tools to improve promptness of diagnosis and more ef-
fective disease modifying therapies, promotion of healthy lifestyle
choices might help to promote neuroprotection and reduce the
risk of PD in the general population.
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